menu
    • menu
    [{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"ENS-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Concerto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concerto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Concerto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Series A Financing","leadProduct":"ENS-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Concerto Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concerto Biosciences \/ Safar Partners","highestDevelopmentStatusID":"2","companyTruncated":"Concerto Biosciences \/ Safar Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Concerto Biosciences

    Menu

    Concerto Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Concerto Biosciences

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Concerto Biosciences

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENS-002

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Concerto Receives FDA IND Clearance for Live Biotherapeutic for Atopic Dermatitis

                            Details : ENS-002 is an investigational live biotherapeutic product (LBP) applied topically, being investigated to treat atopic dermatitis (AD).

                            Product Name : ENS-002

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 26, 2024

                            Lead Product(s) : ENS-002

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Concerto Biosciences

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Concerto Biosciences

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENS-002

                            Therapeutic Area : Dermatology

                            Study Phase : Discovery

                            Sponsor : Safar Partners

                            Deal Size : $23.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline

                            Details : The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.

                            Product Name : ENS-002

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            February 11, 2022

                            Lead Product(s) : ENS-002

                            Therapeutic Area : Dermatology

                            Highest Development Status : Discovery

                            Sponsor : Safar Partners

                            Deal Size : $23.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth